✦ LIBER ✦

Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: Effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide

✍ Scribed by David Hasdai; David R. Holmes Jr; Douglas A. Criger; Eric J. Topol; Robert M. Califf; Robert G. Wilcox; Ernesto Paolasso; Maarten Simoons; Jaap Deckers; Robert A. Harrington; The PURSUIT trial investigators

Book ID: 117008598
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 615 KB
Volume: 139
Category: Article
ISSN: 1097-6744
DOI: 10.1016/s0002-8703(00)90089-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized evaluation of the safety and

Randomized evaluation of the safety and efficacy of enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide

✍ S.G. Goodman; D. Fitchett; P.W. Armstrong; M. Tan; A. Langer 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Timing of Glycoprotein IIb/IIIa Inhibito

Timing of Glycoprotein IIb/IIIa Inhibitor Use and Outcomes Among Patients With Non–ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (Results from CRUSADE)

✍ Pierluigi Tricoci; Eric D. Peterson; Anita Y. Chen; L. Kristin Newby; Robert A. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 164 KB

The Early Glycoprotein IIb/IIIa Inhibiti

The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale

✍ Robert P. Giugliano; L. Kristin Newby; Robert A. Harrington; C. Michael Gibson; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Outcome of acute ST-segment elevation my

Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIB/IIIA inhibition: lessons from the GUSTO V Trial

✍ H.S Gurm; A.M Lincoff; D Lee 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Fondaparinux compared to enoxaparin in p

Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk

✍ Campbell D. Joyner; Ron J.G. Peters; Rizwan Afzal; Susan Chrolavicius; Shamir R. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 266 KB

Randomized evaluation of the efficacy of

Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial

✍ David H. Fitchett; Anatoly Langer; Paul W. Armstrong; Mary Tan; Aurora Mendelsoh 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 142 KB